Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world discontinuation of cBTKi-based treatments in patients with CLL/SLL in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

ZXZhaolin XuPAPaolo Abada

Discussion

Loading...

Member takes

Overview

Retrospective study reveals high early discontinuation rates of cBTKi in chronic lymphocytic leukemia, suggesting a need for better treatment options.

Key Points

  • To analyze the time to treatment discontinuation or death among chronic lymphocytic leukemia patients receiving cBTKi-based treatments.
  • Retrospective observational analysis using Flatiron Health electronic health record database
  • Included adult patients diagnosed with CLL/SLL initiating first cBTKi in first or second line
  • Descriptive statistics and Kaplan-Meier method used for outcome estimation
  • 5520 patients received first cBTKi treatment in first line, with a median follow-up of 35.7 months
  • The median time to treatment discontinuation was 35.4 months for first line overall
  • Approximately one-third of patients discontinued cBTKi treatment by the end of one year

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1bfhttps://doi.org/10.1182/blood-2025-8030
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States2025
  2. 2Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  3. 3Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center2025
  4. 4Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy2025
  5. 5Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025